Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

✍ Scribed by Eron, J. J.; Clotet, B.; Durant, J.; Katlama, C.; Kumar, P.; Lazzarin, A.; Poizot-Martin, I.; Richmond, G.; Soriano, V.; Ait-Khaled, M.; Fujiwara, T.; Huang, J.; Min, S.; Vavro, C.; Yeo, J.; Walmsley, S. L.; Cox, J.; Reynes, J.; Morlat, P.; Vittecoq, D.; Livrozet, J.-M.; Fernandez, P. V.; Gatell, J. M.; DeJesus, E.; DeVente, J.; Lalezari, J. P.; McCurdy, L. H.; Sloan, L. A.; Young, B.; LaMarca, A.; Hawkins, T.

• Book ID: 124157910
• Publisher: University of Chicago Press
• Year: 2012
• Tongue: English
• Weight: 411 KB
• Volume: 207
• Category: Article
• ISSN: 0022-1899
• DOI: 10.1093/infdis/jis750